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The basic helix-loop-helix transcription factor NeuroD1 is required for late events in neuronal differentia-
tion, for maturation of pancreatic  cells, and for terminal differentiation of enteroendocrine cells expressing
the hormone secretin. NeuroD1-null mice demonstrated that this protein is essential for expression of the
secretin gene in the murine intestine, and yet it is a relatively weak transcriptional activator by itself. The
present study shows that Sp1 and NeuroD1 synergistically activate transcription of the secretin gene. NeuroD1,
but not its widely expressed dimerization partner E12, physically interacts with the C-terminal 167 amino acids
of Sp1, which include its DNA binding zinc fingers. NeuroD1 stabilizes Sp1 DNA binding to an adjacent Sp1
binding site on the promoter to generate a higher-order DNA-protein complex containing both proteins and
facilitates Sp1 occupancy of the secretin promoter in vivo. NeuroD-dependent transcription of the genes
encoding the hormones insulin and proopiomelanocortin is potentiated by lineage-specific homeodomain
proteins. The stabilization of binding of the widely expressed transcription factor Sp1 to the secretin promoter
by NeuroD represents a distinct mechanism from other NeuroD target genes for increasing NeuroD-dependent
transcription.
The gene encoding the gut hormone secretin is highly re-
stricted in expression to S-type enteroendocrine cells of the
small intestine in adult animals. In addition, the secretin gene
is expressed transiently during development in pancreatic islets
and in serotonergic neurons of the central nervous system (18,
34). A proximal enhancer localized within 200 bp of the tran-
scription initiation site of the secretin gene is required and
sufficient for its expression in secretin-expressing cells. The
same enhancer is relatively inactive in cell lines that do not
express the endogenous secretin gene (34). Mutational analysis
revealed that the enhancer consists of four distinct protein
binding sites important for transcription. These include two
binding sites for Sp1, one sequence motif that binds to the
DNA binding protein Finb/RREB1 (28), and an E-box that
binds to the basic helix-loop-helix (bHLH) protein NeuroD1
heterodimerized with E12/E47 (20).
NeuroD1 is a member of the tissue-specific class (class B) of
bHLH transcription factors. It is expressed in neurons, the
anterior pituitary gland, pancreatic islets, and enteroendocrine
cells. Thus, NeuroD1 is the only identified protein binding to
the secretin enhancer that is expressed in a very limited num-
ber of cell types, whereas expression of Sp1 and Finb/RREB1
is widespread.
A number of studies suggest a potentially significant role for
NeuroD1 in the terminal differentiation of pancreatic islets
(22, 23) and enteroendocrine cells (21, 22) and in the devel-
opment of various structures in the nervous system (12, 16, 17,
19). Potential target genes that depend on NeuroD1 for ex-
pression include the genes for the hormones secretin, insulin,
glucagon, and proopiomelanocortin (POMC), as well as the
gene encoding the homeodomain protein PDX-1 (4, 21, 23,
26, 30).
Of note, the secretin gene is the only target gene identified
thus far that shows an absolute requirement for NeuroD1 for
in vivo expression. NeuroD1-null mice fail to develop any se-
cretin-producing enteroendocrine cells. A moderate reduction
in the number of glucagon-expressing  cells and insulin-ex-
pressing  cells was noted in the endocrine pancreas, although
both insulin and glucagon immunoreactivity were readily de-
tected in the remaining cells (22). Corticotroph differentiation
was delayed during fetal development in NeuroD1-null mice
with no reduction in POMC-expressing cells in older animals,
indicating a nonessential role for NeuroD1 (15).
In addition to its direct effects on secretin gene transcription,
NeuroD1 may play a role in coordinating expression of secretin
with cell cycle exit as secretin cells terminally differentiate. The
effects of NeuroD1 on cell proliferation may result from in-
creased p21 expression (21). NeuroD1-dependent transcrip-
tion is repressed by cyclin D1 by a mechanism independent of
cyclin-dependent kinases (27). The presence of cyclin D1 in the
proliferating cells of intestinal crypts may serve to prevent
relatively immature, proliferating cells in the intestinal crypts
from prematurely differentiating. Thus, NeuroD1 has a central
role in the regulation of secretin cell differentiation.
Our earlier work suggested that NeuroD1 is a relatively
weak yet essential transcriptional activator of the secretin gene
(28). The organization of the secretin enhancer bears little
similarity to that of the insulin or POMC enhancers, suggesting
that the function of NeuroD1 in transcription of the secretin,
insulin, and POMC genes in enteroendocrine cells, pancreatic
 cells, and pituitary corticotrophs, respectively, may depend
on other factors recruited to each enhancer.
Finb/RREB1, a ubiquitously expressed DNA binding pro-
tein, potentiates transcriptional activation by NeuroD1 despite
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its lack of an intrinsic activation domain. The effect of Finb/
RREB1 on NeuroD1 requires both its binding to the enhancer
5 to the E-box and direct physical association with NeuroD1
(28). We and others previously identified positive cis regula-
tory elements in the secretin gene enhancer that bind to Sp1
(13, 28). One of the Sp1 sites identified was immediately con-
tiguous to the 3 end of the NeuroD1 binding E-box. Because
of the close proximity between these two sites, we examined
whether NeuroD1 and Sp1 functionally and physically interact
to increase the transcription-activating functions of NeuroD1.
Our results suggest that Sp1 and NeuroD1 synergistically ac-
tivate expression of the secretin gene through physical inter-
actions that stabilize binding of Sp1 to DNA.
MATERIALS AND METHODS
Cell culture. The human cervical carcinoma cell lines C33A and HeLa (Amer-
ican Type Culture Collection), the hamster insulin tumor cell line HIT-15 M2.2.2
(hereafter called HIT) (5), and the intestinal tumor cell line STC-1 (29) were
cultured in Dulbecco’s modified Eagle’s medium (4.5 g of glucose/liter) supple-
mented with 10% heat-inactivated fetal calf serum. Drosophila melanogaster
Schneider cells (SL2) were grown at 25°C in Schneider medium (Life Technol-
ogies, Inc.) supplemented with 10% heat-inactivated fetal calf serum.
Plasmid constructions. A secretin-luciferase reporter containing one copy of
the secretin enhancer spanning from 209 to 32 has been described previously
(34). Transversion point mutations were introduced by site-directed mutagenesis
(9) to generate the different mutant secretin reporter plasmids, mGC1 (119,
117); the E-box mutant mE (130, 127) (20); a mutant with both Sp1 sites
mutated, MutGC (65, 63, 119, 117); and a promoter with mutations in
the E-box and both Sp1 binding sites, MutE/GC. The Ins 6 reporter was gener-
ated by inserting 6 bp with a BamHI site between the E-box and the adjacent
GC1 Sp1 binding site by PCR using the wild-type secretin promoter (209 to
32) as a template. The 10-bp insertion between the E-box and the adjacent Sp1
site was generated by digesting the Ins 6 reporter construct with BamHI followed
by end filling and religation. The human telomerase reverse transcriptase
(hTERT)-luciferase construct extending to 629 used in the present study has
been previously described (2). The mammalian expression plasmids for NeuroD1
(23), NeuroD1 in vitro transcription-translation and glutathione S-transferase
(GST) fusion plasmids (21), and Sp1-GST fusion plasmids (8) were previously
described. pacNeuroD1, an expression plasmid for NeuroD1 in insect cells, was
constructed by subcloning NeuroD1 cDNA into BamHI and XhoI sites of the
pacU vector (3). The plasmids encoding short hairpin RNAs (shRNAs) for green
fluorescent protein (GFP) (32) or NeuroD1 (6) under the control of the U6
promoter and their use for reducing expression of each protein were described
earlier.
Transient transfections. Cells were plated at a density of 50,000 per well of
24-well plates 18 h prior to transfection. C33A cells were transfected by calcium
phosphate precipitation with a total of 0.82 g of DNA, consisting of 0.25 g
secretin reporter plasmid, 0.02 g Renilla luciferase plasmid, 0.05 g NeuroD1
expression plasmid, and 0.5 g Sp1 expression plasmid. SL2 cells were trans-
fected similarly except that 0.025 g of Sp1 expression plasmid pacSp1 (3) and
0.25 g of NeuroD1 expression plasmid were used. STC-1 cells were transfected
with Lipofectamine Plus. Cells were harvested 24 h later. Firefly luciferase
activity was normalized to Renilla luciferase activity.
Oligonucleotides. The following oligonucleotides were used in gel shift exper-
iments. The wild-type E-GC1 element encompassing nucleotides137 to96 of
the rat secretin promoter was made by annealing the complementary oligonu-
cleotides (sense strand, AGCGGACGACAGCTGGGGGGGCGGCCCTGAC
CTTCCCGCAAT, and antisense strand, CGATTGCGGGAAGGTCAGGGCC
GCCCCCCCAGCTGTCGTCCG) followed by end filling. Similarly, for making
the E-mGC1 element the oligonucleotides AGCGGACGACAGCTGGGGTG
TCGGCCCTGACCTTCCCGCAAT (sense strand) and CGATTGCGGGAAG
GTCAGGGCCGCACACCCAGCTGTCGTCCG (antisense strand) were an-
nealed, and for making the mE-GC1 element, AGCGGACGATAGTTGGGG
GGGCGGCCCTGACCTTCCCGCAAT (sense strand) and CGATTGCGGG
AAGGTCAGGGCCGCCCCCCCAACTATCGTCCG (antisense strand) were
annealed. The boldface nucleotides indicate mutations introduced into the re-
spective binding sites. In order to insert a 6-bp sequence within the E-GC1 box
the oligonucleotides GCCGGACGACAGCTGGGATCCACGGGGCGGCCC
TGACCTT (sense strand) and GGAAGGTCAGGGCCGCCCCGTGGATCC
CAGCTGTCGTC (antisense strand) were annealed, and to insert a 10-bp se-
quence the oligonucleotides GCCGGACGACAGCTGGGATCGATCCACGG
GGCGGCCCTGACCTT (sense strand) and GGAAGGTCAGGGCCGCCCC
GTGGATCGATCCCAGCTGTCGTC (antisense strand) were annealed.
Gel shift assays. Gel shift assays and nuclear extract preparation were per-
formed as described earlier (28). For reconstitution of DNA-protein complexes
using recombinant Sp1 (Promega) or in vitro-translated proteins, 0.25 g of
poly(dI-dC) was used in each assay. Each reaction was initiated by the addition
of protein followed by incubation for 20 min at room temperature, and then 7 l
was electrophoresed in 4% native polyacrylamide gels. For immunodetection of
proteins in DNA-protein complexes, the extracts were preincubated on ice for
1 h with antibody to NeuroD1 (23), E12 (7), or Sp1 (Santa Cruz Biotechnology).
Coimmunoprecipitation. NeuroD1 was immunoprecipitated from nuclear ex-
tracts (500 g protein) from HIT cells with 2 g of anti-NeuroD1 (Sigma)
antibody. Precipitated proteins were separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose
membrane, and immunoblotted with anti-Sp1 antibody (sc-59; Santa Cruz Bio-
technology).
Binding analysis with GST fusion proteins. Bacterially expressed GST fusion
proteins were adsorbed to glutathione-Sepharose beads and incubated with
[35S]methionine-labeled in vitro-transcribed and -translated proteins, and the
bound proteins were analyzed by SDS-PAGE followed by autoradiography (28).
Chromatin immunoprecipitation (ChIP) assays. Chemical cross-linking of
nuclear proteins to genomic DNA and chromatin fragmentation have been
previously described (33). Cross-linked proteins from precleared chromatin su-
pernatants were immunoprecipitated with anti-NeuroD (Sigma) or anti-Sp1 (sc-
59; Santa Cruz Biotechnology) antibody. DNA was purified (QIAquick PCR
purification kit) following reversal of cross-links and proteinase K digestion.
DNA was amplified with primer pairs described below using semiquantitative
PCR and compared to serially diluted input DNA to ensure that the immuno-
precipitated DNA was present at a concentration that allowed visualization of
different amounts.
The primers used for detecting secretin promoter sequences (forward, 5-CA
GGCTCCGAGGCTTCGC-3, and reverse, 5-GGCCCCTTTATGGCGGCG-
3) have been described earlier (13). For detecting dihydrofolate reductase
(DHFR) promoter sequences, the following primers were used: forward, 5-TG
CACCTGTGGAGGAGGA-3, and reverse, 5-AGAACGCGCGGTCAAGTT-
3. For detection of the transfected secretin promoter, the following primers
were used: forward, 5-GGTACCGCACTACCCT-3, and reverse, 5-TTGGCG
TCTTCCATTTACCA-3 (from the coding sequence of the luciferase gene). The
primers used for detecting the hTERT promoter sequences (forward, 5-GGT
ACCGACCCCCGGGTCCGCCCGGA-3, and reverse, 5-AAGCTTGCTGCC
TGAAACTCGCGCCG-3) were described earlier (35). For detection of the
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) coding region,
the following primers were used: forward, 5-TGAAGGTCGGAGTCAACGG
ATT-3, and reverse, 5-GTTCACACCCATGACGAACATG-3. The PCR
products were separated in 2% agarose gels stained with ethidium bromide.
RESULTS
Synergistic interaction between NeuroD1 and Sp1 on the
secretin promoter. Previous studies showed that expression of
the secretin gene in secretin-expressing cell lines is highly de-
pendent on a NeuroD1 binding E-box. In the rat, mouse, and
human secretin genes, an Sp1 binding site is present adjacent
to the E-box (Fig. 1A). Mutations in the E-box that prevent
binding of NeuroD1 to the enhancer reduced transcriptional
activity of secretin reporter genes by 90% in HIT insulinoma
cells and STC-1 enteroendocrine cells, both of which express
secretin and NeuroD (20). Introduction of point mutations
into the Sp1 binding site (GC1 box) adjacent to the E-box
similarly reduced (84%) transcriptional activity in both cell
lines (Fig. 1B). The importance of these two adjacent sites for
full transcriptional activity prompted us to investigate whether
NeuroD1 and Sp1 functionally cooperate to regulate transcrip-
tion of the secretin gene.
To determine whether Sp1 and NeuroD1 functionally inter-
act, we examined the effects of Sp1 on NeuroD1-dependent
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transcription of the secretin gene as described previously (28)
using transient-expression assays in C33A cells, a cell line that
does not express NeuroD1. Expression of a secretin-luciferase
reporter gene increased by 4.7-fold above the basal level when
coexpressed with NeuroD1, in agreement with our earlier ob-
servations that this bHLH protein has only a modest transac-
tivating function (Fig. 1C). Cotransfection of an Sp1 expres-
sion plasmid increased reporter gene expression by 4.9-fold.
Coexpression of both Sp1 and NeuroD1 increased reporter
expression approximately 32.2-fold, far exceeding the sum of
the activation from either factor alone.
We confirmed that synergistic transcriptional activation of
the secretin gene required the binding sites for both NeuroD1
and Sp1 by expressing both factors with reporter genes con-
taining mutations in either the E-box (20) or GC1 box (28). We
observed no synergism between Sp1 and NeuroD1 with either
mutant, suggesting that their interaction was dependent on
promoter occupancy of their adjacent binding sites (Fig. 1C).
The GC1 mutant reporter was weakly activated by Sp1, prob-
ably from the binding of Sp1 to a second binding site 48
nucleotides 3 to the GC1 box. However, the effects of Sp1
and NeuroD1 on the GC1 mutant reporter were additive,
highlighting the importance of the GC1 site for synergism
(Fig. 1C).
To further assess the function of Sp1 in secretin gene tran-
scription, we examined the activity of the secretin-luciferase
reporter with cotransfected NeuroD1 and/or Sp1 plasmids in
Schneider SL2 cells, which express neither NeuroD1 nor Sp1.
Cotransfection of an Sp1 expression plasmid increased low
basal reporter activity by 6.4-fold. NeuroD1 had no effect by
itself on expression of the secretin reporter in SL2 cells (Fig.
1C). However, NeuroD1 and Sp1 together resulted in a greater-
than-additive (21.2-fold) activation of the reporter gene
in SL2 cells, suggesting that they may functionally interact
(Fig. 1C).
Formation of a ternary DNA-protein complex involves bind-
ing cooperativity between NeuroD1 and Sp1. We examined
DNA-protein complexes formed by Sp1 and NeuroD1 on the
secretin enhancer by electrophoretic mobility shift assays
(EMSAs) to determine if the functional interaction between
these proteins observed in transfection assays was related to
the binding of these factors to the enhancer. It has previously
been shown that NeuroD1 binds to E-boxes as a heterodimer
with ubiquitously expressed bHLH proteins like E12 or E47
but not as a homodimer (23). Binding of in vitro-translated
NeuroD1 and E12 to a probe containing the contiguous E-box
and Sp1 binding site generated a DNA-protein complex rep-
resenting a NeuroD1-E12 heterodimer (Fig. 2A, lane 1),
whereas NeuroD1 alone did not form a complex (not shown).
A distinct, faster-migrating complex was generated with Sp1
(Fig. 2A, lane 3). However, the presence of all three proteins
generated an additional, more slowly migrating complex com-
pared to the complexes produced by Sp1 or NeuroD1-E12
alone (Fig. 2A, lane 2), suggesting the formation of a ternary
complex that contained all three proteins bound to the DNA.
The higher-order complex was not detected if all three pro-
teins were incubated with a probe containing a mutation in
either the E-box or the adjacent Sp1 binding site (Fig. 2A,
lanes 4 and 7) or with a probe containing 6-bp or 10-bp spacing
between the two binding sites (lanes 10 and 11), indicating that
both binding sites as well as their close proximity to each other
were required for the formation of this complex. Although E12
bound to the wild-type probe as a homodimer to generate a
complex, it could not form the more slowly migrating complex
with Sp1 (Fig. 2B, lanes 1 and 2), indicating that NeuroD1
was required for ternary complex formation and that E12
FIG. 1. Transcriptional synergism between NeuroD1 and Sp1 on
the secretin gene. (A) Conserved alignment of the E-box and Sp1
binding sites in the rat, mouse, and human secretin gene promoters.
(B) Loss of transcriptional activity of the secretin reporter in HIT and
STC-1 cells, with mutations in the E-box or the adjacent Sp1 binding
site. Luciferase activity of the E-box mutant (black bars) and GC1
mutant (striped bars) is expressed as a percentage of the wild-type
(white bars) reporter gene activity. Results are shown as the means 
standard errors of the means of three separate experiments done in
duplicate. *, P 	 0.0001. (C) Secretin reporter gene activity in C33A
cells or SL2 cells cotransfected with expression plasmids for NeuroD1,
Sp1, or NeuroD1 plus Sp1 and the reporter plasmids indicated in panel
B. Results are expressed as luciferase activity relative to the activity in
the absence of NeuroD1 or Sp1. The dashed line indicates the sum of
transcriptional activities by NeuroD1 and Sp1 expression vectors co-
transfected individually with the respective reporter. Results are shown
as the means  standard errors of the means for at least five separate
experiments. Significant differences from the additive activities of
NeuroD1 and Sp1 are shown by asterisks (*, P	 0.0001; **, P	 0.05).
WT, wild type.
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homodimers appear to inhibit Sp1 binding to the same probe
molecule.
The synergistic transcriptional activation by NeuroD1 and
Sp1 could arise from interactions that enhance their binding to
DNA. To determine whether the observed ternary complex
resulted from cooperative DNA binding by the two proteins to
the enhancer, we performed an EMSA and quantitated by
phosphorimaging the fraction of probe retained in each DNA-
protein complex generated by Sp1 or NeuroD1/E12 alone as
well the complexes generated by all three proteins together.
Sp1 and NeuroD1/E12 independently bound 15.6% and 6.4%
of the total probe, respectively (Fig. 2C). If Sp1 and NeuroD1-
E12 bound to DNA independently of each other, the proba-
bility of the two proteins simultaneously binding to a single
probe molecule should equal the product of their individual
probabilities of binding. The two proteins together generated a
ternary complex containing approximately 6.7% of the total
probe versus the average predicted value of 1.8% if binding
occurred independently and randomly. This indicates that gen-
eration of the higher-order DNA-protein complex was en-
hanced by cooperative binding interactions.
Ternary complex formation and transactivation depend on
the close proximity of the NeuroD1 and Sp1 binding sites. We
examined DNA-protein complexes generated with the secretin
enhancer probe and nuclear extracts from HIT cells by EMSA
to determine if a similar ternary complex is formed with pro-
teins in crude nuclear extracts as described with purified pro-
teins. A number of DNA-protein complexes were identified,
including one that consisted of several complexes that were not
well resolved on the gel (complex II) (Fig. 3A, lane 1). A
consensus wild-type Sp1 oligonucleotide but not a mutant oli-
gonucleotide completely competed a slowly migrating band
FIG. 2. NeuroD1 and Sp1 bind cooperatively to the secretin gene
to form a ternary DNA-protein complex. (A) EMSA showing protein
complexes formed by indicated combinations of in vitro-translated
NeuroD1, E12, or Sp1 bound to a 32P-labeled probe containing the
E-box and GC1 Sp1 site (lanes 1 to 3) or the same probes with
mutations in either the E-box (lanes 4 to 6) or GC1 (lanes 7 to 9) or
with the insertion of a 6-bp (Ins 6) or a 10-bp (Ins 10) sequence
between the two sites (lanes 10 and 11). The arrowhead denotes a
slow-migrating complex seen only in the presence of all three proteins
(lane 2) but not seen with any of the mutant probes (lanes 4 to 11).
(B) Failure to generate the ternary complex with E12 and Sp1 in the
absence of NeuroD1 (lane 2). (C) Quantitation of Sp1 and NeuroD1/
E12 binding to DNA. The fraction of probe present in complexes
formed by NeuroD1 plus E12 alone (panel A, lane 1) or Sp1 alone
(panel A, lane 3) or in the ternary complex formed by NeuroD1, E12,
and Sp1 together (panel A, lane 2) was measured by phosphorimaging.
Results are shown as the means  standard errors of the means for at
least three separate experiments. *, significantly different (P 	 0.05)
from the fraction predicted for independent binding events measured
as described before (24). WT, wild type.
FIG. 3. Presence of NeuroD1 and Sp1 in a higher-order DNA-
protein complex formed from nuclear extracts. Shown are results of an
EMSA of factors in HIT cell nuclear extract binding to the secretin
promoter regions containing the E-box and adjacent Sp1 binding site.
(A) Effect of competition with unlabeled oligonucleotides for an Sp1,
mutant Sp1 site, or E-box on ternary complex formation. (B) Presence
of Sp1 and NeuroD1 in the ternary complex. Antibodies to NeuroD1
(lane 2) or E12 (lane 5) reduced the slow-migrating complex. Sp1
antibody (lane 3) supershifted the ternary complex. (C) EMSA show-
ing that probes with increased spacing between the E-box and Sp1
binding site cannot generate the ternary complex from nuclear pro-
teins extracted from HIT cells (lanes 2 and 3). (D) Effect of spacing (6
or 10 bp) between the E-box and the adjacent Sp1 binding site on
secretin gene transcription. Luciferase activity of the insertion mutants
is expressed as a percentage of activity of the wild-type reporter gene
transfected in HIT (white bars) or STC-1 (black bars) cells. Results are
shown as the means  standard errors of the means for at least four
independent experiments. Significant differences from the wild type
are shown by an asterisk (P 	 0.001). WT, wild type.
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(complex I), as well as complex III, and partially competed
complex II (Fig. 3A, lane 2 versus lane 3). An Sp1 antibody
completely supershifted the slowly migrating complex I and
reduced the amount of the broad complex II, suggesting that
Sp1 was present in complex I and probably in complex II (Fig.
3B, lane 3). Complex III was minimally altered by the Sp1
antibody, suggesting that it may contain another protein with
an affinity for GC-rich sequences.
Similarly, the more slowly migrating complex I was com-
peted by unlabeled E-box sequences indicating the presence of
bHLH proteins in this complex with Sp1 (Fig. 3A, lane 4).
Antibodies to NeuroD1 (Fig. 3B, lane 2) or E12 (Fig. 3B, lane
5) completely disrupted the formation of complex I, indicating
the presence of NeuroD1 and E12 in addition to Sp1. This
same complex was not generated by extracts of C33A cells,
which do not express NeuroD1 (not shown). Finally insertion
of 6 bp or 10 bp between the E-box and the adjacent Sp1
binding site of the probe disrupted the formation of complex I
without affecting the other complexes, as was shown earlier
with the reconstituted complex I (Fig. 2A). The presence of
both Sp1 and NeuroD1 in complex I as well as its dependence
on the normal spacing between the Sp1 and NeuroD binding
sites indicates that this complex corresponds to the higher-
order complex observed in Fig. 2A with recombinant proteins.
To determine if transcriptional activation also was depen-
dent on the proximity of the E-box to the Sp1 binding site, we
compared the activity of reporter genes where the spacing
between the E-box and the adjacent Sp1 binding site in the
secretin promoter was increased by either 6 bp or 10 bp versus
the wild-type secretin-reporter in two secretin-expressing cell
lines, HIT cells and STC-1 cells. Insertion of either 6 bp or 10
bp significantly reduced the transcriptional activity of the en-
hancer in both cell lines, indicating that the position of the
E-box adjacent to the Sp1 binding site was necessary for max-
imal transcription of the gene (Fig. 3D). Thus, increasing the
spacing between the two sites both reduced transcription and
prevented formation of the higher-order complex, suggesting
that generation of the ternary complex may be required for
maximal transcription.
Sp1 physically associates with NeuroD1. The spacing be-
tween the E-box and GC1 box required for ternary complex
formation and maximal enhancer activity suggested that
NeuroD1 and Sp1 might physically interact with each other.
We immunoprecipitated NeuroD1 from unfractionated ex-
tracts of HIT cells with NeuroD1 antibodies and tested for the
presence of Sp1 by immunoblotting the precipitated proteins
(Fig. 4A). Sp1 antibodies detected a single band in the
NeuroD1 immunoprecipitates (lane 3) but not proteins pre-
cipitated by control immunoglobulin G (IgG) (lane 2), indicat-
ing that Sp1 and NeuroD1 associate at their native levels. To
rule out the possibility that DNA present in extracts led to an
artifactual association between NeuroD1 and Sp1, we repeated
the coimmunoprecipitation experiment with the HIT cell ex-
tracts following pretreatment with ethidium bromide (50 g/
ml) as described before (10). The interaction of NeuroD1 with
Sp1 was not significantly changed by ethidium bromide, indi-
cating that their interaction did not result from the presence of
DNA (not shown). We expressed full-length Sp1 as a GST
fusion protein and tested its ability to directly bind to NeuroD1
using in vitro binding assays. Labeled in vitro-translated
NeuroD1 was retained on an affinity column containing full-
length GST-Sp1, indicating that these two proteins directly
interact with each other (Fig. 4B).
We expressed three deletion mutants of Sp1 as GST fusion
proteins and examined whether they could bind to NeuroD1 to
identify the region of Sp1 that associates with NeuroD1. A
GST fusion protein containing residues 622 to 788 of Sp1 was
sufficient for NeuroD1 binding (Fig. 4B and C). This 167-
FIG. 4. Physical association between Sp1 and NeuroD1. (A) Co-
immunoprecipitation of Sp1 with NeuroD1 in HIT cells. Lane 1 shows
4% of the input used for immunoprecipitation. (B) Sp1 directly inter-
acts with NeuroD1 but not its dimerization partner, E12, through zinc
finger domains. 35S-labeled NeuroD1 (left) or 35S-labeled E12 (right)
was incubated with GST or the indicated GST-Sp1 fusion proteins as
indicated in panel C. NeuroD1 bound to fusion proteins was affinity
isolated, subjected to SDS-PAGE, and detected by autoradiography.
Input lanes were loaded with 10% of the labeled proteins used in the
binding assay. (C) Structure of the Sp1 deletion mutants and summary
of the results. (D and E) Identification of the Sp1 binding domain of
NeuroD1. (D) Wild type or different 35S-labeled NeuroD1 mutants
bound to GST-Sp1 (amino acids 622 to 788) were affinity isolated and
separated by SDS-PAGE (left panel). Input (right panel) lanes were
loaded with 10% of the labeled proteins used in the binding assay.
(E) Structures of the NeuroD1 deletion mutants. WT, wild type; ND,
NeuroD1.
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residue fragment at the C terminus contained the three zinc
fingers of Sp1 that comprise its DNA binding domain. Neither
of two N-terminal transactivation domains rich in serine-threo-
nine and glutamine residues appears to physically interact with
NeuroD1 (Fig. 4B and C). In contrast, E12, the ubiquitously
expressed bHLH dimerization partner of NeuroD1, did not
bind to GST-Sp1, indicating that the interaction between Sp1
and NeuroD1 is specific for NeuroD1 as opposed to other
bHLH proteins capable of binding to the same E-box (Fig. 4B).
To determine the domain of NeuroD1 necessary for interac-
tion with Sp1, we tested the GST-Sp1 fusion containing the C-
terminal 167 amino acids (GST-Sp1622–788) for its ability to bind
to different truncation/deletion mutants of NeuroD1. The 158
amino acids at the N terminus of NeuroD1 were sufficient for
binding to Sp1 (Fig. 4D and E). The inability of the mutant

49/155 to bind Sp1 indicates that the N terminus of NeuroD1,
which contains the bHLH domain, is necessary for Sp1 binding,
whereas the C-terminal activation domain of NeuroD1 does not
appear to be involved. The NeuroD1 deletion mutants 
49/96
and 
113/128 retained the ability to bind to Sp1, suggesting that
the deleted acidic and basic domains and helix 1 were not re-
quired. A final NeuroD1 truncation, N138, which retained 138
residues at the N terminus but lacks helix 2, was unable to bind to
Sp1, suggesting that sequences in helix 2 of the bHLH domain
of NeuroD1 are essential for its association with Sp1 (Fig. 4D
and E).
Sp1 binding to the secretin enhancer is stabilized in Sp1-
NeuroD1 ternary complex. To determine whether the binding
cooperativity between NeuroD1 and Sp1 arises from stabilized
DNA binding of either protein in the presence of the other, we
compared the relative stability of the ternary complex com-
pared to complexes generated by Sp1 or NeuroD1/E12 alone
by EMSA. In order to better resolve the ternary complex from
the complexes generated by either Sp1 alone or NeuroD1/E12,
we used the truncated GST-Sp1622–788 fusion protein that con-
tains both the DNA binding and NeuroD1-interacting domains
of Sp1. The truncated Sp1 protein by itself generated a fast-
migrating DNA-protein complex (complex iii, Fig. 5A, lane 2)
that was easily resolved from the slower-migrating complex
produced by NeuroD1/E12 (complex ii, Fig. 5A, lane 1). A
more slowly migrating complex appeared with NeuroD1/E12
and GST-Sp1622–788 (complex i) (Fig. 5A, lane 3), suggesting
that the truncated Sp1 protein could form the ternary complex
as well. All three complexes (i, ii, and iii) were competed by an
excess of unlabeled competitor containing the contiguous E-
box and Sp1 binding site added to the probe prior to the
binding reaction, indicating that all complexes resulted from
sequence-specific DNA binding (lane 4).
We compared the stabilities of each of the three DNA-
protein complexes by measuring their rate of dissociation after
equilibrium binding following addition of an excess of compet-
ing DNA fragments. For these studies we incubated GST-
Sp1622–788, NeuroD1, and E12 with a probe containing the
contiguous E-box and Sp1 binding site. Upon completion of
the binding reaction, a 500-fold excess of unlabeled probe
DNA was added and samples were withdrawn every 4 min for
EMSA (Fig. 5B). The amount of probe remaining in each
complex was quantitated for each time point by phosphor-
imaging (Fig. 5C). The results indicated that the dissociation of
the Sp1-DNA complex (complex iii) was much faster than that
of the Sp1-NeuroD1/E12-DNA complex (complex i). Only
35% of the probe initially present in complex iii remained after
4 minutes, and only 22% remained after 8 minutes. In contrast,
the rate of loss of complex i or ii was lower than that of
complex iii at all of the time points examined, suggesting that
both the NeuroD1/E12 and ternary complexes were more sta-
ble than the complex generated by Sp1. The relative stability of
the ternary complex (complex i) suggests that Sp1 binding is
stabilized in the presence of NeuroD1 bound to the adjacent
E-box, potentially accounting for its enhanced formation.
To determine whether NeuroD1 stabilizes Sp1 binding to
the secretin promoter in vivo, we examined the effects of
NeuroD1 on chromatin occupancy of the secretin enhancer by
Sp1. As expected ChIP assays revealed no occupancy of the
secretin enhancer by NeuroD1 in HeLa cells, which do not
FIG. 5. Stabilization of Sp1-DNA binding in the ternary DNA-
protein complex with NeuroD1. (A) EMSA performed with indicated
recombinant proteins and a probe containing the contiguous E-box
and Sp1 binding site. Slower-migrating complex i represents the ter-
nary DNA-protein complex (lane 3) whereas complexes ii (lanes 1 and
3) and iii (lanes 2 and 3) were generated by NeuroD1-E12 and Sp1,
respectively. All three complexes were competed by a 100-fold molar
excess of the unlabeled probe added to the probe prior to the binding
reaction. (B) An EMSA where a 500-fold molar excess of unlabeled
oligonucleotide competitor was added after the probe and proteins
reached equilibrium. Aliquots were removed at 4-minute intervals and
quickly loaded onto an acrylamide gel for electrophoresis. (C) Time
course of dissociation of DNA-protein complexes. The percentage of
probe remaining in complexes with Sp1 alone (complex iii), with
NeuroD1-E12 (complex ii), or with NeuroD1-E12-Sp1 (complex i) was
quantitated by phosphorimaging and plotted relative to the zero time
point. Results are shown as the means  standard errors of the means
for three separate experiments. *, significantly different (complex iii in
comparison to complex i or complex ii; P 	 0.01).
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normally express NeuroD1 (Fig. 6A, top panel, lane 5). How-
ever, in HeLa cells transfected with a NeuroD1 expression
plasmid we readily identified the presence of NeuroD1 at the
secretin enhancer in vivo (top panel, lane 10) but not at the
DHFR promoter, which lacks a NeuroD1 binding site (bottom
panel, lane 10), indicating that transiently expressed NeuroD1
was associated with the endogenous secretin gene.
ChIP assays showed occupancy of the endogenous secretin
promoter by Sp1 in NeuroD1-expressing HeLa cells, whereas
recruitment of Sp1 was minimal in control HeLa cells, suggest-
ing that NeuroD1 increases recruitment of Sp1 to the secretin
promoter (Fig. 6B, left panel). The DHFR promoter contains
several Sp1 binding sites. Recruitment of Sp1 to the DHFR
promoter appeared identical in both wild-type HeLa cells and
HeLa cells expressing NeuroD1, indicating that promoter oc-
cupancy by Sp1 is not generally dependent on NeuroD1 (Fig.
6B, middle panel). The dependence on NeuroD1 for Sp1 bind-
ing appears to be specific for the secretin gene. Little signal was
detected with control IgG or with the GAPDH gene, which
lacks Sp1 binding sites, confirming the specificity of protein-
DNA complexes immunoprecipitated in ChIP assays for the
secretin or the DHFR promoter (Fig. 6B).
We further confirmed the importance of NeuroD1 for oc-
cupancy of the secretin promoter by Sp1 in vivo in NeuroD1-
expressing STC-1 enteroendocrine cells by knocking down
NeuroD1 expression by DNA-based RNA interference using a
previously described NeuroD shRNA (6). We used transient
ChIP assays (11) to examine occupancy of a transiently trans-
fected secretin promoter by endogenous NeuroD1 or Sp1.
Both Sp1 and NeuroD1 were recruited to the wild-type pro-
moter but not to a mutant promoter containing mutations in
the E-box and both Sp1 sites (MutE/GC) that prevent binding
of either factor to DNA (Fig. 7A, lanes 5 and 6). Introduction
of mutations into the Sp1 binding sites of secretin promoter
slightly reduced NeuroD1 occupancy, suggesting that Sp1 DNA
binding is not essential for NeuroD1 recruitment to the promoter
(Fig. 7A, lane 6).
We next transfected STC-1 cells with the wild-type secretin
reporter plasmid or a control reporter plasmid containing mul-
tiple Sp1 binding sites (hTERT-Luc) plus expression plasmids
for either a NeuroD1 shRNA or a GFP shRNA, which served
as a control. The NeuroD1 shRNA significantly reduced
FIG. 6. NeuroD1 facilitates interaction of Sp1 with the secretin
enhancer. (A) Recruitment of transiently expressed NeuroD1 to the
endogenous secretin promoter in HeLa cells. ChIP experiments were
performed using soluble chromatin fragments prepared from HeLa
cells transfected with an expression plasmid for E12 in the absence ()
or the presence () of a NeuroD1 expression plasmid. DNA purified
from the chromatin input or the immunoprecipitate (-NeuroD1 or
control IgG) was amplified by PCR for 32 cycles with primers covering
the secretin promoter (284 to 57) (top panel) or a control pro-
moter (310 to 17 of human DHFR) (bottom panel). (B) Effect of
NeuroD1 on recruitment of Sp1 to the secretin promoter in vivo. ChIP
experiments were performed with anti-Sp1 antibody (-Sp1) as de-
scribed for panel A. The human GAPDH gene served as a negative
control (right).
FIG. 7. Depletion of NeuroD1 in STC-1 cells reduces recruitment
of Sp1 to the secretin promoter. Shown are results of transient ChIP
assays for transfected secretin and hTERT promoters. (A) Sp1 and
NeuroD1 occupancy of the wild-type secretin promoter (top panel), a
secretin promoter with mutations in the Sp1 binding sites (MutGC;
middle panel), and a mutant (MutE/GC) secretin promoter lacking
Sp1 and NeuroD1 binding sites (bottom panel) in STC-1 cells. (B) Ef-
fect of NeuroD1 depletion on transient ChIP of Sp1 and NeuroD1 in
STC-1 cells cotransfected with a plasmid containing the secretin pro-
moter (left) or hTERT promoter (right). Cells were cotransfected with
either shRNA plasmids for NeuroD1 or GFP as a control. The final
DNA extractions were PCR amplified for detection of the transfected
promoters using pairs of primers described in Materials and Methods.
(C) Effect of NeuroD1 depletion on transcription of a secretin reporter
gene in STC-1 cells cotransfected with shRNA plasmids for NeuroD1
and GFP as indicated. Results are shown as the means  standard
errors of the means of at least three separate experiments. , signifi-
cantly different from control or GFP shRNAs (P 	 0.01).
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NeuroD1 occupancy of the secretin promoter, indicating a
significant decrease in the level of NeuroD1 expression (Fig.
7B, left panel). The effectiveness of the NeuroD1 shRNA was
further confirmed by an 85% loss of secretin promoter activity
(Fig. 7C). We consistently observed a significant reduction in
Sp1 promoter occupancy in cells with decreased expression of
NeuroD1, whereas Sp1 occupancy of the hTERT promoter
was unaffected by depletion of NeuroD1 (Fig. 7B, left versus
right panel). These observations suggest that in secretin-ex-
pressing cells, NeuroD1 stabilizes Sp1 binding to the secretin
enhancer to potentiate secretin gene transcription.
DISCUSSION
Mice carrying a targeted deletion of the bHLH protein
NeuroD1 fail to develop secretin-expressing enteroendocrine
cells, indicating that this protein is essential for secretin gene
expression. Paradoxically, in vitro studies suggest that NeuroD1
is a relatively weak activator of the secretin gene transcription
by itself. Of the transcription factors that bind to the secretin
enhancer, only NeuroD1 is relatively restricted to a limited
number of cell types, as opposed to the ubiquitous expression
of the others, implying a major role for NeuroD1 in regulating
secretin gene expression. In the present work, we show that
physical interactions between NeuroD1 and the ubiquitously
expressed transcription factor Sp1 on the secretin gene en-
hancer significantly potentiate transactivation by this tissue-
specific class B bHLH protein. We previously identified the
protein Finb/RREB1 as a transcription-modifying protein that
synergistically potentiates NeuroD1. Thus, the interaction of
NeuroD1 with two widely expressed DNA binding proteins is
one mechanism for potentiating the relatively weak transacti-
vating function of NeuroD1.
Cell-type-specific gene expression depends on the presence
of a combination of transcription factors, some of which are
also highly restricted in expression, as well as the organization
transcription factor binding sites controlling a gene. The prox-
imal enhancer of the secretin gene is conserved in different
mammalian species, maintaining a nearly identical arrange-
ment of four cis regulatory elements including the E-box and
immediately adjacent Sp1 binding site. The close proximity of
these two sites appears to be essential for the synergism be-
tween Sp1 and NeuroD1. Finb/RREB1, which binds to se-
quences upstream of the E-box, appears to be an unusual class
of transcription-modifying protein. Although Finb/RREB1 is
present in corepressor complexes with CtBP (31), it serves to
potentiate NeuroD1-dependent transcription despite the ab-
sence of an intrinsic activation domain or any direct activation
of transcription by itself. In contrast to coactivators, Finb must
bind to DNA to modify the activity of NeuroD1.
The interaction of NeuroD1 with Sp1 through regions close
to the DNA binding domain of each protein may in part ex-
plain why synergistic transcriptional activation depends on the
adjacent positions of the E-box and Sp1 binding sites. This
interaction results in cooperative DNA binding and stabilized
Sp1 DNA binding in the resultant ternary DNA-protein com-
plex with NeuroD1 and E12.
The promoters of several muscle-specific genes including the
regulatory region of human cardiac alpha-actin promoter and
troponin I promoter have Sp1 binding sites in close proximity
to E-boxes that bind to myogenic bHLH proteins (1, 14). The
HLH domain of the myogenic bHLH protein myogenin, like
NeuroD1, physically associates with the C-terminal zinc finger
domain of Sp1. However, it is not known whether myogenin
and Sp1 increase transcription of the cardiac actin promoter
in an additive or synergistic manner. In this promoter, the
E-box and Sp1 site are separated by an additional 10 nucleo-
tides, or approximately one complete helical turn, compared to
the secretin enhancer. Introduction of 10 additional nucleo-
tides between the secretin gene E-box and the adjacent Sp1
site abrogated their synergistic effects on transcription.
Besides the secretin gene, relatively few target genes that are
directly activated by NeuroD1 have been identified. These
include the genes encoding the hormones insulin and POMC.
Expression of both of these genes depends on interactions
between bHLH proteins with lineage-restricted homeodomain
transcription factors bound to nearby cis elements to potenti-
ate the transactivating function of NeuroD1.
Lineage-specific transcription of the POMC gene in the pi-
tuitary gland is enhanced by the functional synergy between
bHLH factors binding to an E-box and the pituitary gland-
specific homeodomain protein Pitx-1 (25). Pitx-1 indirectly
modifies NeuroD1-dependent transcription by physically inter-
acting with one of its ubiquitously expressed dimerization part-
ners rather than by a direct association with NeuroD1. The
bHLH domain of Pan1 (E47) serves as a protein-protein in-
teraction domain with the homeodomain of Pitx-1. The
NeuroD1 binding E-box in the POMC promoter is separated
from the Pitx-1 binding site by 67 bp. This spacing may indicate
that the interactions on the POMC promoter involve different
surfaces of the bHLH proteins than in the case of the insulin
and secretin promoter, where Pdx1 and Sp1 bind to sites im-
mediately adjacent to the E-box.
Insulin-expressing pancreatic  cells arise from the primitive
gut endoderm and are developmentally related to enteroendo-
crine cells, and yet insulin gene expression does not occur in
the intestine. The expression of insulin and secretin genes, two
NeuroD1-dependent genes, in distinct cell types depends in
part on the expression of different sets of transcriptional acti-
vators in islets versus enteroendocrine cells and on the orga-
nization of transcription factor binding sites on each promoter.
The major elements responsible for -cell-specific transcrip-
tion of the insulin gene are localized to a relatively small region
of the promoter that contains an E-box and two TAAT-rich A
elements that bind to the homeodomain protein PDX-1. In
developing animals, PDX-1 is expressed throughout the prox-
imal duodenum and the pancreas, but intestinal expression is
largely absent in adult animals, whereas expression in islets
continues.
The homeodomain of PDX-1 associates with several other
proteins including E47, NeuroD1, and high-mobility-group
protein Y1 to form a higher-order transcription-activating
complex (24). Unlike the specific interaction between
NeuroD1 and Sp1 on the secretin gene, PDX-1 interacts with
the ubiquitous dimerization partners of NeuroD1 as well as
with NeuroD1. In the case of the insulin gene, synergistic
transcriptional activation occurs with E47 as well as NeuroD1.
In addition, high-mobility-group protein Y1 synergizes with
the other members of the insulin gene-transactivating complex.
The absence of PDX-1 in adult enteroendocrine cells may
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explain in part why insulin is not expressed in the intestine.
Thus, NeuroD1-dependent expression of the insulin and se-
cretin genes in pancreatic  cells and S-type enteroendocrine
cells, respectively, depends on different sets of transcription
factors that interact with NeuroD1 to potentiate its activity.
NeuroD1 plays an important role in regulating terminal dif-
ferentiation of neurons and hormone-producing cell lineages.
Relatively few target genes have been identified for this bHLH
protein. Other DNA binding proteins potentiate transactiva-
tion of the genes encoding the hormones POMC, insulin, and
secretin by NeuroD1. The enhancer of the secretin gene shares
little with the organization of the insulin or POMC genes.
Unlike the POMC and insulin genes, where NeuroD1 syner-
gizes with homeodomain proteins specific for their tissue,
NeuroD1 synergizes with the widely expressed proteins Sp1
and RREB1 to increase secretin gene transcription. The spe-
cific arrangement of factor binding sites in the secretin en-
hancer provides the critical context for the interaction with Sp1
and Finb that potentiates the activating function of NeuroD1.
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